Company Filing History:
Years Active: 2024-2025
Title: Yanling Mi: Innovator in Monoclonal Antibody Development
Introduction
Yanling Mi is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies for tumor immunotherapy. With a total of 3 patents to his name, his work is paving the way for innovative treatments in cancer therapy.
Latest Patents
Yanling Mi's latest patents include groundbreaking inventions in the realm of humanized monoclonal antibodies. One of his notable patents is the "Humanized anti-human OX40 monoclonal antibody, preparation method therefor and use thereof." This invention relates to a humanized anti-human OX40 monoclonal antibody that exhibits high affinity and specificity for OX40. It stimulates T cells to secrete cytokines, thereby activating the OX40 signaling pathway and achieving the goal of tumor immunotherapy.
Another significant patent is the "Humanized anti-human PD-L1 monoclonal antibody and preparation method therefor and use thereof." This invention focuses on a humanized anti-human PD-L1 monoclonal antibody that also demonstrates high affinity and specificity for PD-L1. It stimulates T cells to secrete cytokines and presents a new mechanism of immune checkpoint regulation, which is crucial for enhancing the efficacy of cancer treatments.
Career Highlights
Yanling Mi is currently associated with Nanjing Genscript Biotech Co., Ltd., where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential impact on cancer immunotherapy, making him a key figure in this area of research.
Collaborations
Throughout his career, Yanling Mi has collaborated with notable colleagues, including Liusong Yin and Zhuo Fang. These collaborations have further enriched his research and contributed to the advancement of monoclonal antibody technologies.
Conclusion
In summary, Yanling Mi is a distinguished inventor whose work in monoclonal antibodies is making significant strides in cancer immunotherapy. His innovative patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.